Coherus Biosciences (NASDAQ:CHRS)‘s stock had its “buy” rating reissued by equities research analysts at Maxim Group in a report issued on Friday, March 9th, MarketBeat Ratings reports. They presently have a $15.00 price objective on the biotechnology company’s stock, down from their prior price objective of $20.00. Maxim Group’s target price would suggest a potential upside of 37.61% from the stock’s previous close.
Several other brokerages have also recently issued reports on CHRS. BidaskClub upgraded Coherus Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Zacks Investment Research cut Coherus Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, ValuEngine upgraded Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $29.33.
CHRS traded up $0.65 during trading hours on Friday, hitting $10.90. The company’s stock had a trading volume of 525,328 shares, compared to its average volume of 801,746. Coherus Biosciences has a fifty-two week low of $8.05 and a fifty-two week high of $24.70. The stock has a market cap of $664.56, a P/E ratio of -2.43 and a beta of 3.39. The company has a debt-to-equity ratio of 3.33, a current ratio of 5.12 and a quick ratio of 5.12.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Temasek Holdings Private Ltd bought a new stake in shares of Coherus Biosciences during the 3rd quarter worth $87,524,000. Vanguard Group Inc. boosted its stake in shares of Coherus Biosciences by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 2,255,467 shares of the biotechnology company’s stock worth $32,367,000 after acquiring an additional 46,223 shares in the last quarter. Citadel Advisors LLC boosted its stake in shares of Coherus Biosciences by 819.9% during the 4th quarter. Citadel Advisors LLC now owns 1,772,241 shares of the biotechnology company’s stock worth $15,595,000 after acquiring an additional 1,579,582 shares in the last quarter. State Street Corp boosted its stake in shares of Coherus Biosciences by 26.8% during the 2nd quarter. State Street Corp now owns 1,416,572 shares of the biotechnology company’s stock worth $20,329,000 after acquiring an additional 298,986 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of Coherus Biosciences by 5.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 1,393,661 shares of the biotechnology company’s stock worth $12,264,000 after acquiring an additional 72,710 shares in the last quarter. 82.29% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Maxim Group Reiterates “Buy” Rating for Coherus Biosciences (CHRS)” was originally published by BBNS and is owned by of BBNS. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://baseballnewssource.com/2018/04/03/coherus-biosciences-chrs-given-a-15-00-price-target-at-maxim-group/2014799.html.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.